2 medical experts criticize FDA approval of high-dose Aricept

The FDA's authorization of a higher dose of Aricept, an Alzheimer's disease drug marketed by Eisai and Pfizer, went against reviewers' advice and regulatory standard, Steven Woloshin and Lisa Schwartz of Dartmouth College wrote in BMJ. They said 23-milligram Aricept did not significantly improve cognitive and overall function and caused harmful side effects during a clinical study. Furthermore, the label and ads for the formulation contain misleading statements, the authors wrote.

View Full Article in:

Medical Marketing & Media · New York Times (tiered subscription model), The

Published in Briefs: